If you have been reading about Ipamorelin and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-05-12. Where a claim depends on a specific study, the study is described rather than over-claimed.
Lyophilized material is generally held at minus twenty degrees Celsius or lower, protected from moisture and light. Repeated excursions to room temperature cause condensation inside the vial and gradual moisture uptake, both of which shorten shelf life. Containers should be allowed to equilibrate before opening so that water does not condense on the solid. Dividing a batch into single-use aliquots reduces freeze-thaw cycling. Solid peptide handled this way is usually considered stable for months to years, while the same material in solution degrades on a much shorter timescale.
Common solvents for laboratory work include water, buffered saline, and dimethyl sulfoxide. Once dissolved, the peptide is exposed to hydrolysis and oxidation, and alkaline conditions accelerate breakdown. Low-binding plasticware and the addition of a carrier protein reduce losses to container surfaces, which can otherwise be substantial at low concentrations. Solutions are typically kept cold and used within days. Investigators working with the compound generally prepare fresh working dilutions rather than storing dilute stocks, and they avoid repeated warming of the same vial.
Research quantities of ipamorelin are typically distributed as a white to off-white lyophilized powder. The solid dissolves readily in water and in aqueous buffers, and stock solutions are commonly prepared in sterile water or a mildly acidic diluent. Adsorption to plastic and glass surfaces can reduce the concentration of very dilute solutions, so containers and transfer steps deserve attention when accurate concentrations matter. Reconstituted material is generally used promptly rather than held for extended periods.
Storage recommendations for the dry solid center on low temperature and low moisture, most often -20 °C in a sealed, desiccated container protected from light. Solutions are less stable than the powder and are usually kept cold and used within a short window. Freeze-thaw cycling is a recognized source of loss, and aliquoting before freezing is a standard precaution. These practices derive from general peptide handling principles rather than from a single published stability trial, so exact shelf lives should be treated as approximate.
Analytical confirmation relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry for identity and purity assessment. Mass spectrometry distinguishes the intact molecule from truncation products and from oxidation or deamidation variants that share similar chromatographic retention. Immunoassays appear in some biological studies but can cross-react with related peptides, so they are weaker tools for identity work. Reported purity figures depend heavily on the gradient, detector, and integration method used, which complicates direct comparison between laboratories.
| Property | Value | Notes |
|---|---|---|
| Purity method | Reversed-phase HPLC | C18 column, UV detection at 214 nm |
| Identity method | Mass spectrometry | Electrospray or MALDI-TOF |
| Solubility | Soluble in water and DMSO | Dissolution may require brief mixing |
| Storage temperature | -20 °C or lower | Desiccated and protected from light |
| Counterion form | Trifluoroacetate or acetate | Affects measured peptide content |
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Compared with earlier growth hormone secretagogues such as GHRP-6 and hexarelin, ipamorelin has been reported to produce less stimulation of adrenocorticotropic hormone, cortisol, and prolactin in animal and early human studies. This selectivity is usually attributed to differences in receptor subtype interactions and to the tissue distribution of the receptor. Effects on appetite appear weaker than those of ghrelin itself, although the supporting evidence base is small. Whether these differences produce a distinct clinical profile remains an open question, since controlled human trials are limited.
Ipamorelin is a synthetic pentapeptide first described in the 1990s by researchers at Novo Nordisk during a program to develop selective growth hormone secretagogues. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues, alpha-aminoisobutyric acid and D-2-naphthylalanine. The C-terminus is amidated, and the material is supplied as a white lyophilized powder. The molecular formula is C38H49N9O5 and the monoisotopic mass is approximately 711.85 daltons. The short chain and modified residues give it greater resistance to enzymatic degradation than many larger peptide hormones.
At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor type 1a, the same G protein-coupled receptor that binds ghrelin. Receptor activation couples to Gq/11 signaling, raising intracellular calcium through inositol trisphosphate and diacylglycerol, which in turn promotes exocytosis of growth hormone from pituitary somatotroph cells. Ipamorelin binds this receptor with high affinity and shows weak activity at other secretagogue-related targets in vitro. Its action requires the intact receptor and is not reversed by growth hormone-releasing hormone antagonists.
Published discussion of this compound is uneven. Some references describe it as a tool for probing growth hormone regulation, while others focus on analytical characterization or on comparisons with related secretagogues. Statements about selectivity, half-life and potency often trace back to a small number of original reports that later authors cite secondhand. Readers evaluating a claim should therefore check whether a figure reflects a direct measurement or a repeated citation, and whether the underlying study was conducted in animals, in isolated cells or in human volunteers.
Identity and purity assessment for a research peptide of this kind typically combines reversed-phase high-performance liquid chromatography with mass spectrometry. The chromatographic run separates related impurities and yields a purity percentage, while electrospray ionization or matrix-assisted laser desorption mass spectrometry confirms the expected molecular mass. Amino acid analysis or tandem mass spectrometry sequencing can add confidence when material is intended for quantitative work. Laboratories differ in how they calculate and report purity, so figures from different sources are not always directly comparable.
== Coaching career == Immediately after Hird retired from playing football, there was much speculation as to whether he would be interested in a coaching role at a club in the AFL, but primarily at Essendon. After initially dodging questions about his future, Hird stated in August 2010 that "There's something in me, deep in my heart, that says at some point I want to coach Essendon". These words came as a surprise to many, including former premiership teammate Matthew Lloyd, who said that Hird had "changed his whole persona in regards to how he's answering his questions... Just in regards to saying, 'I'll coach one day. I want to coach Essendon one day'. Even those type of words, I haven't heard before." These comments by Hird, considered to be Essendon's "favourite son", furthered speculation towards the future of then-Essendon coach Matthew Knights. A rumour emerged following these comments suggesting that Hird was part of an unofficial agreement with the Essendon board to replace Matthew Knights for the 2011 AFL Season. However, two days after Hird's initial comments, he announced that he had changed his mind due to the intense division and speculation over Matthew Knights' future following Hird's initial comments. Hird stated that he was ruling himself out of coaching Essendon for at least three years.
=== Myeloid cells === The effects of TGF-β1 on macrophages and monocytes are predominantly suppressive; this cytokine can inhibit the proliferation of these cells and prevent their production of reactive oxygen (e.g. superoxide (O2−)) and nitrogen (e.g. nitric oxide (NO)) intermediates. However, as with other cell types, TGF-β1 can also have the opposite effect on cells of myeloid origin. For example, TGF-β1 acts as a chemoattractant, directing an immune response to certain pathogens. Likewise, macrophages and monocytes respond to low levels of TGF-β1 in a chemotactic manner. Furthermore, the expression of monocytic cytokines (such as interleukin(IL)-1α, IL-1β, and TNF-α), and macrophage's phagocytic can be increased by the action of TGF-β1. TGF-β1 reduces the efficacy of the MHC II in astrocytes and dendritic cells, which in turn decreases the activation of appropriate helper T cell populations.
== Scope and terminology == Traditional packaging protects a product through physical barriers, structural strength, closures, and containment. Passive barrier materials may reduce the movement of oxygen, water vapour, light, aromas, or contaminants without actively changing the internal package environment. A package is normally classified as active when it contains a component designed to absorb, release, or otherwise interact with a substance in the product or package atmosphere. Examples include oxygen scavengers, moisture absorbers, antimicrobial agents, ethylene scavengers, and carbon-dioxide emitters. Vacuum-sealed pouches and low-permeability multilayer films are not automatically active packaging. They remain passive systems unless they are combined with an intentionally reactive or releasing component. Intelligent systems differ from active systems because their main function is to sense, record, display, or communicate information.
Sources: en.wikipedia.org
ADP-dependent NAD(P)H-hydrate dehydratase (EC 4.2.1.136, (6S)-β-6-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ADP-hydrolysing), (6S)-6-β-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ADP-hydrolysing, NADH-forming)) is an enzyme with systematic name (6S)-6β-hydroxy-1,4,5,6-tetrahydronicotinamide-adenine-dinucleotide hydro-lyase (ADP-hydrolysing; NADH-forming). This enzyme catalyses the following chemical reaction
Somalia was likely one of the first lands to be settled by early humans due to its location. Hunter-gatherers who would later migrate out of Africa likely settled here before their migrations. During the Stone Age, the Doian and Hargeisan cultures flourished here. The oldest evidence of burial customs in the Horn of Africa comes from cemeteries in Somalia dating back to the 4th millennium BC. The stone implements from the Jalelo site in the north were also characterised in 1909 as important artefacts demonstrating the archaeological universality during the Paleolithic between the East and the West. According to linguists, the first Afroasiatic-speaking populations arrived in the region during the ensuing Neolithic period from the family's proposed urheimat ("original homeland") in the Nile Valley, or the Near East. The Laas Geel complex on the outskirts of Hargeisa in northwestern Somalia dates back approximately 5,000 years, and has rock art depicting both wild animals and decorated cows. Other cave paintings are found in the northern Dhambalin region, which feature one of the earliest known depictions of a hunter on horseback. The rock art is dated to 1,000 to 3,000 BC. Additionally, between the towns of Las Khorey and El Ayo in northern Somalia lies Karinhegane, the site of numerous cave paintings, which collectively have been estimated to be around 2,500 years old. The camel is believed to have been domesticated in the Horn region between the 2nd and 3rd millennium BC. From there, it spread to Egypt and the Maghreb.
==== Eurasian plate ==== Eifel hotspot (8) 50°12′N 6°42′E, w= 1 az= 082° ±8° rate= 12 ±2 mm/yr Iceland hotspot (14) 64°24′N 17°18′W Eurasian Plate, w= 0.8 az= 075° ±10° rate= 5 ±3 mm/yr North American Plate, w= 0.8 az= 287° ±10° rate= 15 ±5 mm/yr Possibly related to the North Atlantic continental rifting (62 Ma), Greenland. Azores hotspot (1) 37°54′N 26°00′W Eurasian Plate, w= 0.5 az= 110° ±12° North American Plate, w= 0.3 az= 280° ±15° Jan Mayen hotspot (15) 71°00′N 9°00′W Hainan hotspot (46) 20°00′N 110°00′E, az= 000° ±15°
Sources: en.wikipedia.org
It is reported as the percentage of total peak area in a reversed-phase chromatogram. That number does not reflect water content, residual solvents, or counterions. The actual peptide content is therefore lower than the stated purity figure suggests.
Trifluoroacetate and acetate are common in lyophilized peptide preparations. They contribute to the mass of the powder without contributing to the peptide itself. This shifts the true content and can affect results in biological assays.
Hydrolysis and oxidation are the primary pathways. Alkaline conditions accelerate hydrolytic cleavage of the chain. Oxidation most often involves susceptible residues, producing products that appear as earlier or later peaks in chromatographic analysis.
Typical guidance is -20 °C in a sealed container with desiccant and protection from light. The powder tolerates handling better than a solution, but repeated warming and cooling is still avoided.